Oxime reactivators of acetylcholinesterase are commonly used to treat highly toxic organophosphate poisoning. They are effective nucleophiles that can restore the catalytic activity of acetylcholinesterase; however, their main limitation is the difficulty in crossing the blood-brain barrier (BBB) because of their strongly hydrophilic nature. Various approaches to overcome this limitation and enhance the bioavailability of oxime reactivators in the CNS have been evaluated; these include structural modifications, conjugation with molecules that have transporters in the BBB, bypassing the BBB through intranasal delivery, and inhibition of BBB efflux transporters. A promising approach is the use of nanoparticles (NPs) as the delivery systems. Studies using mesoporous silica nanomaterials, poly (L-lysine)-graft-poly(ethylene oxide) NPs, metallic organic frameworks, poly(lactic-co-glycolic acid) NPs, human serum albumin NPs, liposomes, solid lipid NPs, and cucurbiturils, have shown promising results. Some NPs are considered as nanoreactors for organophosphate detoxification; these combine bioscavengers with encapsulated oximes. This study provides an overview and critical discussion of the strategies used to enhance the bioavailability of oxime reactivators in the central nervous system.

Biomedical Research Centre University Hospital in Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic

Faculty of Science Department of Chemistry University of Hradec Kralove Rokitanskeho 62 500 03 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Agrawal M, Saraf S, Saraf S et al (2020) Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release 321:372–415. https://doi.org/10.1016/j.jconrel.2020.02.020 PubMed DOI

Albuquerque EX, Pereira EFR, Aracava Y et al (2006) Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. PNAS 103:13220–13225. https://doi.org/10.1073/pnas.0605370103 PubMed DOI PMC

Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515. https://doi.org/10.1021/mp800051m PubMed DOI PMC

Almáši M, Zeleňák V, Gyepes R et al (2020) A series of four novel alkaline earth metal–organic frameworks constructed of Ca( ii ), Sr( ii ), Ba( ii ) ions and tetrahedral MTB linker: structural diversity, stability study and low/high-pressure gas adsorption properties. RSC Adv 10:32323–32334. https://doi.org/10.1039/D0RA05145D PubMed DOI PMC

Amin MdL (2013) P-glycoprotein Inhibition for optimal drug delivery. Drug Target Insights 7:27–34. https://doi.org/10.4137/DTI.S12519 PubMed DOI PMC

Andrýs R, Klusoňová A, Lísa M, Karasová JŽ (2020) Encapsulation of oxime acetylcholinesterase reactivators: influence of physiological conditions on the stability of oxime-cucurbit[7]uril complexes. New J Chem 44:14367–14372. https://doi.org/10.1039/D0NJ03102J DOI

Andrýs R, Klusoňová A, Lísa M et al (2021) Effect of oxime encapsulation on acetylcholinesterase reactivation: pharmacokinetic study of the asoxime–cucurbit[7]uril complex in mice using hydrophilic interaction liquid chromatography-mass spectrometry. Mol Pharm 18:2416–2427. https://doi.org/10.1021/acs.molpharmaceut.1c00257 PubMed DOI

Antonijevic B, Stojiljkovic MP (2007) Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin Med Res 5:71–82. https://doi.org/10.3121/cmr.2007.701 PubMed DOI PMC

Arnott JA, Planey SL (2012) The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 7:863–875. https://doi.org/10.1517/17460441.2012.714363 PubMed DOI

Ashani Y, Bhattacharjee AK, Leader H et al (2003) Inhibition of cholinesterases with cationic phosphonyl oximes highlights distinctive properties of the charged pyridine groups of quaternary oxime reactivators. Biochem Pharmacol 66:191–202. https://doi.org/10.1016/s0006-2952(03)00204-1 PubMed DOI

Atanasov VN, Petrova I, Dishovsky C (2013) In vitro investigation of efficacy of new reactivators on OPC inhibited rat brain acetylcholinesterase. Chem Biol Interact 203:139–143. https://doi.org/10.1016/j.cbi.2012.11.020 PubMed DOI

Bajgar J (2004) Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Advances in clinical chemistry. Elsevier, pp 151–216

Bajgar J, Fusek J, Kuca K et al (2007) Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev Med Chem 7:461–466. https://doi.org/10.2174/138955707780619581 PubMed DOI

Barjasteh M, Vossoughi M, Bagherzadeh M, Bagheri KP (2022) Green synthesis of PEG-coated MIL-100(Fe) for controlled release of dacarbazine and its anticancer potential against human melanoma cells. Int J Pharm 618:121647. https://doi.org/10.1016/j.ijpharm.2022.121647 PubMed DOI

Becker C, Worek F, John H (2010) Chromatographic analysis of toxic phosphylated oximes (POX): a brief overview. Drug Test Anal 2:460–468. https://doi.org/10.1002/dta.167 PubMed DOI

Bester SM, Guelta MA, Cheung J et al (2018) Structural insights of stereospecific inhibition of human acetylcholinesterase by VX and subsequent reactivation by HI-6. Chem Res Toxicol 31:1405–1417. https://doi.org/10.1021/acs.chemrestox.8b00294 PubMed DOI

Bhonsle JB, Causey R, Oyler BL et al (2013) Evaluation and computational characterization of the facilitated transport of Glc carbon C-1 oxime reactivators across a blood brain barrier model. Chem Biol Interact 203:129–134. https://doi.org/10.1016/j.cbi.2012.09.012 PubMed DOI

Brambilla D, Le Droumaguet B, Nicolas J et al (2011) Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine 7:521–540. https://doi.org/10.1016/j.nano.2011.03.008 PubMed DOI

Buzyurova DN, Pashirova TN, Zueva IV et al (2020) Surface modification of pralidoxime chloride-loaded solid lipid nanoparticles for enhanced brain reactivation of organophosphorus-inhibited AChE: pharmacokinetics in rat. Toxicology 444:152578. https://doi.org/10.1016/j.tox.2020.152578 PubMed DOI

Chatzikleanthous D, O’Hagan DT, Adamo R (2021) Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines. Mol Pharm 18:2867–2888. https://doi.org/10.1021/acs.molpharmaceut.1c00447 PubMed DOI

Chen X, Tong R, Shi Z et al (2018) MOF nanoparticles with encapsulated autophagy inhibitor in controlled drug delivery system for antitumor. ACS Appl Mater Interfaces 10:2328–2337. https://doi.org/10.1021/acsami.7b16522 PubMed DOI

Chigumira W, Maposa P, Gadaga LL et al (2015) Preparation and evaluation of pralidoxime-loaded PLGA nanoparticles as potential carriers of the drug across the blood brain barrier. J Nanomater 2015:e692672. https://doi.org/10.1155/2015/692672 DOI

Choi YH, Liu F, Kim JS et al (1998) Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J Control Release 54:39–48. https://doi.org/10.1016/s0168-3659(97)00174-0 PubMed DOI

Da Silva O, Probst N, Landry C et al (2022) A new class of Bi- and trifunctional sugar oximes as antidotes against organophosphorus poisoning. J Med Chem 65:4649–4666. https://doi.org/10.1021/acs.jmedchem.1c01748 PubMed DOI PMC

Dadparvar M, Wagner S, Wien S et al (2011) HI 6 human serum albumin nanoparticles–development and transport over an in vitro blood-brain barrier model. Toxicol Lett 206:60–66. https://doi.org/10.1016/j.toxlet.2011.06.027 PubMed DOI

Dadparvar M, Wagner S, Wien S et al (2014) Freeze-drying of HI-6-loaded recombinant human serum albumin nanoparticles for improved storage stability. Eur J Pharm Biopharm 88:510–517. https://doi.org/10.1016/j.ejpb.2014.06.008 PubMed DOI

Dail MB, Meek EC, Chambers HW, Chambers JE (2019) In vitro P-glycoprotein activity does not completely explain in vivo efficacy of novel centrally effective oxime acetylcholinesterase reactivators. Drug Chem Toxicol 42:403–408. https://doi.org/10.1080/01480545.2018.1461902 PubMed DOI

Daraee H, Etemadi A, Kouhi M et al (2016) Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol 44:381–391. https://doi.org/10.3109/21691401.2014.953633 PubMed DOI

Dong J-H, Ma Y, Li R et al (2021) Smart MSN-drug-delivery system for tumor cell targeting and tumor microenvironment release. ACS Appl Mater Interfaces 13:42522–42532. https://doi.org/10.1021/acsami.1c14189 PubMed DOI

Dreis S, Rothweiler F, Michaelis M et al (2007) Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 341:207–214. https://doi.org/10.1016/j.ijpharm.2007.03.036 PubMed DOI

Ellman GL, Courtney KD, Andres V, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95. https://doi.org/10.1016/0006-2952(61)90145-9 PubMed DOI

Estevez J, Vilanova E (2009) Model equations for the kinetics of covalent irreversible enzyme inhibition and spontaneous reactivation: esterases and organophosphorus compounds. Crit Rev Toxicol 39:427–448. https://doi.org/10.1080/10408440802412309 PubMed DOI

Evans OR, Xiong R-G, Wang Z et al (1999) Crystal engineering of acentric diamondoid metal-organic coordination networks. Angew Chem Int Ed Engl 38:536–538. https://doi.org/10.1002/(SICI)1521-3773(19990215)38:4%3c536::AID-ANIE536%3e3.0.CO;2-3 PubMed DOI

Eyer P, Hell W, Kawan A, Klehr H (1986) Studies on the decomposition of the oxime HI 6 in aqueous solution. Arch Toxicol 59:266–271. https://doi.org/10.1007/BF00290549 PubMed DOI

Eyer P, Hagedorn I, Ladstetter B (1988) Study on the stability of the oxime HI 6 in aqueous solution. Arch Toxicol 62:224–226. https://doi.org/10.1007/BF00570145 PubMed DOI

Fan N, Li Q, Liu Y et al (2023) Preparation of an HI-6-loaded brain-targeted liposomes based on the nasal delivery route and the evaluation of its reactivation of central toxic acetylcholinesterase. Eur J Pharm Sci. https://doi.org/10.1016/j.ejps.2023.106406 PubMed DOI

Fundarò A, Cavalli R, Bargoni A et al (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 42:337–343. https://doi.org/10.1006/phrs.2000.0695 PubMed DOI

Gänger S, Schindowski K (2018) Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 10:E116. https://doi.org/10.3390/pharmaceutics10030116 DOI

Gao H, Pang Z, Jiang X (2013) Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res 30:2485–2498. https://doi.org/10.1007/s11095-013-1122-4 PubMed DOI

Garcia GE, Campbell AJ, Olson J et al (2010) Novel oximes as blood-brain barrier penetrating cholinesterase reactivators. Chem-Biol Interact 187:199–206. https://doi.org/10.1016/j.cbi.2010.02.033 PubMed DOI

Gastaldi L, Battaglia L, Peira E et al (2014) Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 87:433–444. https://doi.org/10.1016/j.ejpb.2014.05.004 PubMed DOI

Gaydess A, Duysen E, Li Y et al (2010) Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. Chem Biol Interact 187:295–298. https://doi.org/10.1016/j.cbi.2010.01.005 PubMed DOI PMC

Gentile P, Chiono V, Carmagnola I, Hatton PV (2014) An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci 15:3640–3659. https://doi.org/10.3390/ijms15033640 PubMed DOI PMC

Ghitman J, Biru EI, Stan R, Iovu H (2020) Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine. Mater Des 193:108805. https://doi.org/10.1016/j.matdes.2020.108805 DOI

Giri S, Trewyn BG, Stellmaker MP, Lin VS-Y (2005) Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl 44:5038–5044. https://doi.org/10.1002/anie.200501819 PubMed DOI

Gorecki L, Korabecny J, Musilek K et al (2016) SAR study to find optimal cholinesterase reactivator against organophosphorous nerve agents and pesticides. Arch Toxicol 90:2831–2859. https://doi.org/10.1007/s00204-016-1827-3 PubMed DOI

Gorecki L, Korabecny J, Musilek K et al (2017) Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006–2016). Expert Opin Ther Patents 27:971–985. https://doi.org/10.1080/13543776.2017.1338275 DOI

Gorecki L, Hepnarova V, Karasova JZ et al (2021) Development of versatile and potent monoquaternary reactivators of acetylcholinesterase. Arch Toxicol 95:985–1001. https://doi.org/10.1007/s00204-021-02981-w PubMed DOI

Handl J, Malinak D, Capek J et al (2021) Effects of charged oxime reactivators on the HK-2 cell line in renal toxicity screening. Chem Res Toxicol 34:699–703. https://doi.org/10.1021/acs.chemrestox.0c00489 PubMed DOI

Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9:S5. https://doi.org/10.1186/1471-2202-9-S3-S5 PubMed DOI PMC

Hartlieb KJ, Ferris DP, Holcroft JM et al (2017) Encapsulation of ibuprofen in CD-MOF and related bioavailability studies. Mol Pharm 14:1831–1839. https://doi.org/10.1021/acs.molpharmaceut.7b00168 PubMed DOI

Heldman E, Ashani Y, Raveh L, Rachaman ES (1986) Sugar conjugates of pyridinium aldoximes as antidotes against organophosphate poisoning. Carbohyd Res 151:337–347. https://doi.org/10.1016/S0008-6215(00)90353-7 DOI

Hervé F, Ghinea N, Scherrmann J-M (2008) CNS Delivery Via Adsorptive Transcytosis. The AAPS Journal 10:455–472. https://doi.org/10.1208/s12248-008-9055-2 PubMed DOI PMC

Hoyos-Ceballos GP, Ruozi B, Ottonelli I et al (2020) PLGA-PEG-ANG-2 nanoparticles for blood-brain barrier crossing: proof-of-concept study. Pharmaceutics 12:E72. https://doi.org/10.3390/pharmaceutics12010072 DOI

Huxford RC, Della Rocca J, Lin W (2010) Metal–organic frameworks as potential drug carriers. Curr Opin Chem Biol 14:262–268. https://doi.org/10.1016/j.cbpa.2009.12.012 PubMed DOI PMC

Jain KK (2012) Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (lond) 7:1225–1233. https://doi.org/10.2217/nnm.12.86 PubMed DOI

Jeong HC, Kang NS, Park N-J et al (2009) Reactivation potency of fluorinated pyridinium oximes for acetylcholinesterases inhibited by paraoxon organophosphorus agent. Bioorg Med Chem Lett 19:1214–1217. https://doi.org/10.1016/j.bmcl.2008.12.070 PubMed DOI

Jett DA, Spriggs SM (2020) Translational research on chemical nerve agents. Neurobiol Dis 133:104335. https://doi.org/10.1016/j.nbd.2018.11.020 PubMed DOI

Jokanović M (2012) Structure-activity relationship and efficacy of pyridinium oximes in the treatment of poisoning with organophosphorus compounds: a review of recent data. Curr Top Med Chem 12:1775–1789 PubMed DOI

Joosen M, van der Schans M, van Dijk C et al (2011) Increasing oxime efficacy by blood-brain barrier modulation. Toxicol Lett 206:67–71. https://doi.org/10.1016/j.toxlet.2011.05.231 PubMed DOI

Karasova J, Petr S, Kuca K (2010) In vitro screening of blood-brain barrier penetration of clinically used acetylcholinesterase reactivators. J Appl Biomed 10:35–40. https://doi.org/10.2478/v10136-009-0005-9 DOI

Karasova JZ, Zemek F, Bajgar J et al (2011) Partition of bispyridinium oximes (trimedoxime and K074) administered in therapeutic doses into different parts of the rat brain. J Pharm Biomed Anal 54:1082–1087. https://doi.org/10.1016/j.jpba.2010.11.024 PubMed DOI

Karasova JZ, Chladek J, Hroch M et al (2013) Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma: pharmacokinetic study of oxime K027 and trimedoxime. J Appl Toxicol 33:18–23. https://doi.org/10.1002/jat.1699 PubMed DOI

Kassa J, Karasova JZ, Caisberger F et al (2010a) A comparison of reactivating and therapeutic efficacy of the oxime K203 and its fluorinated analog (KR-22836) with currently available oximes (obidoxime, trimedoxime, HI-6) against tabun in rats and mice. J Enzyme Inhib Med Chem 25:480–484. https://doi.org/10.3109/14756360903257918 PubMed DOI

Kassa J, Karasova JZ, Tesarova S et al (2010b) A comparison of neuroprotective efficacy of the oxime K203 and its fluorinated analogue (KR-22836) with obidoxime in tabun-poisoned rats. Basic Clin Pharmacol Toxicol 107:861–867. https://doi.org/10.1111/j.1742-7843.2010.00588.x PubMed DOI

Kilianova Z, Ciznarova N, Szmicsekova K et al (2020) Expression of cholinesterases and their anchoring proteins in rat heart. Can J Physiol Pharmacol 98:473–476. https://doi.org/10.1139/cjpp-2019-0565 PubMed DOI

Kim S-N, Kim J, Kim H-Y et al (2013) Adsorption/catalytic properties of MIL-125 and NH2–MIL-125. Catal Today 204:85–93. https://doi.org/10.1016/j.cattod.2012.08.014 DOI

Kitagawa S, Kitaura R, Noro S (2004) Functional porous coordination polymers. Angew Chem Int Ed 43:2334–2375. https://doi.org/10.1002/anie.200300610 DOI

Kobrlova T, Soukup O (2020) Effect of P-glycoprotein on the availability of oxime reactivators in the brain. Toxicology 443:152541. https://doi.org/10.1016/j.tox.2020.152541 PubMed DOI

Kobrlova T, Korabecny J, Soukup O (2019) Current approaches to enhancing oxime reactivator delivery into the brain. Toxicology 423:75–83. https://doi.org/10.1016/j.tox.2019.05.006 PubMed DOI

Kresge CT, Leonowicz ME, Roth WJ et al (1992) Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359:710–712. https://doi.org/10.1038/359710a0 DOI

Krishnan JKS, Arun P, Appu AP et al (2016) Intranasal delivery of obidoxime to the brain prevents mortality and CNS damage from organophosphate poisoning. Neurotoxicology 53:64–73. https://doi.org/10.1016/j.neuro.2015.12.020 PubMed DOI PMC

Kuca K, Jun D, Musilek K (2006) Structural requirements of acetylcholinesterase reactivators. Mini-Rev Med Chem 6:269–277 PubMed DOI

Kuca K, Musilova L, Palecek J et al (2009) Novel bisquaternary oximes—reactivation of acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon. Molecules 14:4915–4921. https://doi.org/10.3390/molecules14124915 PubMed DOI PMC

Kufleitner J, Wagner S, Worek F et al (2010) Adsorption of obidoxime onto human serum albumin nanoparticles: drug loading, particle size and drug release. J Microencapsul 27:506–513. https://doi.org/10.3109/02652041003681406 PubMed DOI

Kumar S, Malik MM, Purohit R (2017) Synthesis methods of mesoporous silica materials. Mater Today: Proc 4:350–357. https://doi.org/10.1016/j.matpr.2017.01.032 DOI

Kuznetsova DA, Gaynanova GA, Vasilieva EA et al (2022) Oxime therapy for brain AChE reactivation and neuroprotection after organophosphate poisoning. Pharmaceutics 14:1950. https://doi.org/10.3390/pharmaceutics14091950 PubMed DOI PMC

Lagona J, Mukhopadhyay P, Chakrabarti S, Isaacs L (2005) The cucurbit[n]uril family. Angew Chem Int Ed 44:4844–4870. https://doi.org/10.1002/anie.200460675 DOI

Li H, Eddaoudi M, O’Keeffe M, Yaghi OM (1999) Design and synthesis of an exceptionally stable and highly porous metal-organic framework. Nature 402:276–279. https://doi.org/10.1038/46248 DOI

Li P, Moon S-Y, Guelta MA et al (2016) Nanosizing a metal-organic framework enzyme carrier for accelerating nerve agent hydrolysis. ACS Nano 10:9174–9182. https://doi.org/10.1021/acsnano.6b04996 PubMed DOI

Li Z, Wang C, Chen J et al (2021) uPAR targeted phototheranostic metal-organic framework nanoprobes for MR/NIR-II imaging-guided therapy and surgical resection of glioblastoma. Mater Des 198:109386. https://doi.org/10.1016/j.matdes.2020.109386 DOI

Liang YQ, Tang XC (2004) Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 361:56–59. https://doi.org/10.1016/j.neulet.2003.12.071 PubMed DOI

Lin Y-S, Haynes CL (2010) Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc 132:4834–4842. https://doi.org/10.1021/ja910846q PubMed DOI

Locatelli E, Comes Franchini M (2012) Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanopart Res 14:1316. https://doi.org/10.1007/s11051-012-1316-4 DOI

Lockridge O (2015) Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 148:34–46. https://doi.org/10.1016/j.pharmthera.2014.11.011 PubMed DOI

Lorke DE, Kalasz H, Petroianu GA, Tekes K (2008) Entry of oximes into the brain: a review. Curr Med Chem 15:743–753. https://doi.org/10.2174/092986708783955563 PubMed DOI

Lu J, Liong M, Li Z et al (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6:1794–1805. https://doi.org/10.1002/smll.201000538 PubMed DOI PMC

Lunt J (1998) Large-scale production, properties and commercial applications of polylactic acid polymers. Polym Degrad Stab 59:145–152. https://doi.org/10.1016/S0141-3910(97)00148-1 DOI

Lushington GH, Guo J-X, Hurley MM (2006) Acetylcholinesterase: molecular modeling with the whole toolkit. Curr Top Med Chem 6:57–73. https://doi.org/10.2174/156802606775193293 PubMed DOI

Maček Hrvat N, Zorbaz T, Šinko G, Kovarik Z (2018) The estimation of oxime efficiency is affected by the experimental design of phosphylated acetylcholinesterase reactivation. Toxicol Lett 293:222–228. https://doi.org/10.1016/j.toxlet.2017.11.022 PubMed DOI

Manzano M, Vallet-Regí M (2018) Mesoporous silica nanoparticles in nanomedicine applications. J Mater Sci: Mater Med 29:65. https://doi.org/10.1007/s10856-018-6069-x PubMed DOI

Marrs TC (2004) The role of diazepam in the treatment of nerve agent poisoning in a civilian population. Toxicol Rev 23:145–157. https://doi.org/10.2165/00139709-200423030-00002 PubMed DOI

Martínez-Carmona M, Lozano D, Baeza A et al (2017) A novel visible light responsive nanosystem for cancer treatment. Nanoscale 9:15967–15973. https://doi.org/10.1039/C7NR05050J PubMed DOI

Masson P, Lockridge O (2010) Butyrylcholinesterase for protection from organophosphorus poisons; catalytic complexities and hysteretic behavior. Arch Biochem Biophys 494:107. https://doi.org/10.1016/j.abb.2009.12.005 PubMed DOI

Masson E, Ling X, Joseph R et al (2012) Cucurbituril chemistry: a tale of supramolecular success. RSC Adv 2:1213–1247. https://doi.org/10.1039/C1RA00768H DOI

Maurice T, Strehaiano M, Siméon N et al (2016) Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse. Behav Brain Res 296:351–360. https://doi.org/10.1016/j.bbr.2015.08.026 PubMed DOI

McGuinn WD, Cannon EP, Chui CT et al (1993) The encapsulation of squid diisopropylphosphorofluoridate-hydrolyzing enzyme within mouse erythrocytes. Fundam Appl Toxicol 21:38–43. https://doi.org/10.1006/faat.1993.1069 PubMed DOI

McKinlay AC, Xiao B, Wragg DS et al (2008) Exceptional behavior over the whole adsorption−storage−delivery cycle for NO in porous metal organic frameworks. J Am Chem Soc 130:10440–10444. https://doi.org/10.1021/ja801997r PubMed DOI

Meng H, Mai WX, Zhang H et al (2013) Co-delivery of an optimal drug/siRNA combination using mesoporous silica nanoparticle to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7:994–1005. https://doi.org/10.1021/nn3044066 PubMed DOI PMC

Mercey G, Verdelet T, Saint-André G et al (2011) First efficient uncharged reactivators for the dephosphylation of poisoned human acetylcholinesterase. Chem Commun (camb) 47:5295–5297. https://doi.org/10.1039/c1cc10787a PubMed DOI

Mercey G, Verdelet T, Renou J et al (2012) Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res 45:756–766. https://doi.org/10.1021/ar2002864 PubMed DOI

Mondloch JE, Katz MJ, Isley WC et al (2015) Destruction of chemical warfare agents using metal-organic frameworks. Nat Mater 14:512–516. https://doi.org/10.1038/nmat4238 PubMed DOI

Mostaghaci B, Hanifi A, Loretz B, Lehr C-M (2011) Nano-particulate calcium phosphate as a gene delivery system. InTech DOI

Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for drug delivery. Nat Mater 12:991–1003. https://doi.org/10.1038/nmat3776 PubMed DOI

Ohta H, Ohmori T, Suzuki S et al (2006) New safe method for preparation of sarin-exposed human erythrocytes acetylcholinesterase using non-toxic and stable sarin analogue isopropyl p-nitrophenyl methylphosphonate and its application to evaluation of nerve agent antidotes. Pharm Res 23:2827–2833. https://doi.org/10.1007/s11095-006-9123-1 PubMed DOI

Okuno S, Sakurada K, Ohta H et al (2008) Blood–brain barrier penetration of novel pyridinealdoxime methiodide (PAM)-type oximes examined by brain microdialysis with LC-MS/MS. Toxicol Appl Pharmacol 227:8–15. https://doi.org/10.1016/j.taap.2007.09.021 PubMed DOI

Paris JL, Cabañas MV, Manzano M, Vallet-Regí M (2015) Polymer-grafted mesoporous silica nanoparticles as ultrasound-responsive drug carriers. ACS Nano 9:11023–11033. https://doi.org/10.1021/acsnano.5b04378 PubMed DOI

Pashirova TN, Zueva IV, Petrov KA et al (2017) Nanoparticle-delivered 2-PAM for rat brain protection against paraoxon central toxicity. ACS Appl Mater Interfaces 9:16922–16932. https://doi.org/10.1021/acsami.7b04163 PubMed DOI

Pashirova TN, Braïki A, Zueva IV et al (2018a) Combination delivery of two oxime-loaded lipid nanoparticles: time-dependent additive action for prolonged rat brain protection. J Control Release 290:102–111. https://doi.org/10.1016/j.jconrel.2018.10.010 PubMed DOI

Pashirova TN, Zueva IV, Petrov KA et al (2018b) Mixed cationic liposomes for brain delivery of drugs by the intranasal route: the acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Colloids Surf B Biointerfaces 171:358–367. https://doi.org/10.1016/j.colsurfb.2018.07.049 PubMed DOI

Pashirova TN, Bogdanov A, Masson P (2021) Therapeutic nanoreactors for detoxification of xenobiotics: concepts, challenges and biotechnological trends with special emphasis to organophosphate bioscavenging. Chem Biol Interact 346:109577. https://doi.org/10.1016/j.cbi.2021.109577 PubMed DOI

Pastorino F, Brignole C, Di Paolo D et al (2019) Overcoming biological barriers in neuroblastoma therapy: the vascular targeting approach with liposomal drug nanocarriers. Small. https://doi.org/10.1002/smll.201804591 PubMed DOI

Pei L, Omburo G, Mcguinn WD et al (1994) Encapsulation of phosphotriesterase within murine erythrocytes. Toxicol Appl Pharmacol 124:296–301. https://doi.org/10.1006/taap.1994.1035 PubMed DOI

Petrikovics I, Hong K, Omburo G et al (1999) Antagonism of paraoxon intoxication by recombinant phosphotriesterase encapsulated within sterically stabilized liposomes. Toxicol Appl Pharmacol 156:56–63. https://doi.org/10.1006/taap.1998.8620 PubMed DOI

Petrikovics I, Wales M, Budai M et al (2012) Nano-intercalated organophosphorus-hydrolyzing enzymes in organophosphorus antagonism. AAPS PharmSciTech 13:112–117. https://doi.org/10.1208/s12249-011-9728-5 PubMed DOI

Pulkrabkova L, Svobodova B, Konecny J et al (2023) Neurotoxicity evoked by organophosphates and available countermeasures. Arch Toxicol 97:39–72. https://doi.org/10.1007/s00204-022-03397-w PubMed DOI

Qu M, Lin Q, He S et al (2018) A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson’s disease. J Control Release 277:173–182. https://doi.org/10.1016/j.jconrel.2018.03.019 PubMed DOI

Rachaman ES, Ashani Y, Leader H et al (1979) Sugar-oximes, new potential antidotes against organophosphorus poisoning. Arzneimittelforschung 29:875–876. https://doi.org/10.1002/chin.197938312 PubMed DOI

Radu DR, Lai C-Y, Jeftinija K et al (2004) A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J Am Chem Soc 126:13216–13217. https://doi.org/10.1021/ja046275m PubMed DOI

Rastegari E, Hsiao Y-J, Lai W-Y et al (2021) An update on mesoporous silica nanoparticle applications in nanomedicine. Pharmaceutics 13:1067. https://doi.org/10.3390/pharmaceutics13071067 PubMed DOI PMC

Rochu D, Chabrière E, Masson P (2007) Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 233:47–59. https://doi.org/10.1016/j.tox.2006.08.037 PubMed DOI

Rosenberg YJ, Mao L, Jiang X et al (2017) Post-exposure treatment with the oxime RS194B rapidly reverses early and advanced symptoms in macaques exposed to sarin vapor. Chem Biol Interact 274:50–57. https://doi.org/10.1016/j.cbi.2017.07.003 PubMed DOI PMC

Rosenberg YJ, Wang J, Ooms T et al (2018) Post-exposure treatment with the oxime RS194B rapidly reactivates and reverses advanced symptoms of lethal inhaled paraoxon in macaques. Arch Toxicol 293:229–234. https://doi.org/10.1016/j.toxlet.2017.10.025 DOI

Sakurada K, Ohta H (2020) No promising antidote 25 years after the Tokyo subway sarin attack: a review. Legal Med 47:101761. https://doi.org/10.1016/j.legalmed.2020.101761 PubMed DOI

Sakurada K, Matsubara K, Shimizu K, et al (2003) Pralidoxime iodide (2-PAM) penetrates across the blood–brain barrier. Neurochem Res 28:1401–1407. https://doi.org/10.1023/A:1024960819430 PubMed DOI

Sánchez-López E, Espina M, Doktorovova S et al (2017) Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye—part II—ocular drug-loaded lipid nanoparticles. Eur J Pharm Biopharm 110:58–69. https://doi.org/10.1016/j.ejpb.2016.10.013 PubMed DOI

Schinkel (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179–194. https://doi.org/10.1016/s0169-409x(98)00085-4 PubMed DOI

Seyfoddin A, Shaw J, Al-Kassas R (2010) Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 17:467–489. https://doi.org/10.3109/10717544.2010.483257 PubMed DOI

Sharom FJ (2011) The P-glycoprotein multidrug transporter. Essays Biochem 50:161–178. https://doi.org/10.1042/bse0500161 PubMed DOI

Shen L, Zhang Y, Cai Q et al (2023) HI-6-loaded PEGylated liposomes: an on-site first-aid strategy for acute organophosphorus agent poisoning. Drug Deliv 30:20–27. https://doi.org/10.1080/10717544.2022.2152132 PubMed DOI

Shi Z, Zhou Y, Fan T et al (2020) Inorganic nano-carriers based smart drug delivery systems for tumor therapy. Smart Mater Med 1:32–47. https://doi.org/10.1016/j.smaim.2020.05.002 DOI

Soukup O, Korabecny J, Malinak D et al (2018) In vitro and in silico evaluation of non-quaternary reactivators of AChE as antidotes of organophosphorus poisoning—a new hope or a blind alley? Med Chem 14:281–292. https://doi.org/10.2174/1573406414666180112105657 PubMed DOI

Stephanopoulos N, Tong GJ, Hsiao SC, Francis MB (2010) Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. ACS Nano 4:6014–6020. https://doi.org/10.1021/nn1014769 PubMed DOI

Szilasi M, Budai M, Budai L, Petrikovics I (2012) Nanoencapsulated and microencapsulated enzymes in drug antidotal therapy. Toxicol Ind Health 28:522–531. https://doi.org/10.1177/0748233711416946 PubMed DOI

Tan SY, Ang CY, Zhao Y (2017) 5.17—Smart therapeutics achieved via host-guest assemblies. In: Atwood JL (ed) Comprehensive supramolecular chemistry II. Elsevier, Oxford, pp 391–420 DOI

Terrier F, Rodriguez-Dafonte P, Guével EL, Moutiers G (2006) Revisiting the reactivity of oximate α-nucleophiles with electrophilic phosphorus centers. Relevance to detoxification of sarin, soman and DFP under mild conditions. Org Biomol Chem 4:4352–4363. https://doi.org/10.1039/B609658C PubMed DOI

Tesarova B, Musilek K, Rex S, Heger Z (2020) Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery. J Control Release 325:176–190. https://doi.org/10.1016/j.jconrel.2020.06.026 PubMed DOI

Thiermann H, Zilker T, Eyer F et al (2009) Monitoring of neuromuscular transmission in organophosphate pesticide-poisoned patients. Toxicol Lett 191:297–304. https://doi.org/10.1016/j.toxlet.2009.09.013 PubMed DOI

Thompson CM, Gerdes JM, VanBrocklin HF (2020) Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures. Neurobiol Dis 133:104455. https://doi.org/10.1016/j.nbd.2019.04.011 PubMed DOI

Topczewski JJ, Quinn DM (2013) Kinetic assessment of N-methyl-2-methoxypyridinium species as phosphonate anion methylating agents. Org Lett 15:1084–1087. https://doi.org/10.1021/ol400054m PubMed DOI PMC

Tougu V (2001) Acetylcholinesterase: mechanism of catalysis and inhibition. Curr Med Chem Central Nerv Syst Agents 1:155–170 DOI

Vallet-Regí M (2006) Ordered mesoporous materials in the context of drug delivery systems and bone tissue engineering. Chemistry: A Eur J 12:5934–5943. https://doi.org/10.1002/chem.200600226 DOI

Vallet-Regi M, Rámila A, del Real RP, Pérez-Pariente J (2001) A new property of MCM-41: drug delivery system. Chem Mater 13:308–311. https://doi.org/10.1021/cm0011559 DOI

Vilela SMF, Salcedo-Abraira P, Colinet I et al (2017) Nanometric MIL-125–NH2 metal–organic framework as a potential nerve agent antidote carrier. Nanomaterials (basel) 7:321. https://doi.org/10.3390/nano7100321 PubMed DOI PMC

Wagner S, Kufleitner J, Zensi A et al (2010) Nanoparticulate transport of oximes over an in vitro blood–brain barrier model. PLoS ONE 5:e14213. https://doi.org/10.1371/journal.pone.0014213 PubMed DOI PMC

Wang M, Thanou M (2010) Targeting nanoparticles to cancer. Pharmacol Res 62:90–99. https://doi.org/10.1016/j.phrs.2010.03.005 PubMed DOI

Wang L, Li L, Fan Y, Wang H (2013) Host-guest supramolecular nanosystems for cancer diagnostics and therapeutics. Adv Mater 25:3888–3898. https://doi.org/10.1002/adma.201301202 PubMed DOI

Wang M, Zhou C, Chen J et al (2015) Multifunctional biocompatible and biodegradable folic acid conjugated poly(ε-caprolactone)–polypeptide copolymer vesicles with excellent antibacterial activities. Bioconjugate Chem 26:725–734. https://doi.org/10.1021/acs.bioconjchem.5b00061 DOI

Wang W et al (2016) Nanoscale metal-organic framework-hemoglobin conjugates. Chem, Asian J. https://doi.org/10.1002/asia.201501216 PubMed DOI

Watson A, Opresko D, Young RA et al (2015) Chapter 9—Organophosphate nerve agents. In: Gupta RC (ed) Handbook of toxicology of chemical warfare agents, 2nd edn. Academic Press, Boston, pp 87–109 DOI

Winter M, Wille T, Musilek K et al (2016) Investigation of the reactivation kinetics of a large series of bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase. Toxicol Lett 244:136–142. https://doi.org/10.1016/j.toxlet.2015.07.007 PubMed DOI

Worek F, Thiermann H (2013) The value of novel oximes for treatment of poisoning by organophosphorus compounds. Pharmacol Ther 139:249–259. https://doi.org/10.1016/j.pharmthera.2013.04.009 PubMed DOI

Worek F, Szinicz L, Eyer P, Thiermann H (2005) Evaluation of oxime efficacy in nerve agent poisoning: development of a kinetic-based dynamic model. Toxicol Appl Pharmacol 209:193–202. https://doi.org/10.1016/j.taap.2005.04.006 PubMed DOI

Worek F, Wille T, Koller M, Thiermann H (2016) Toxicology of organophosphorus compounds in view of an increasing terrorist threat. Arch Toxicol 90:2131–2145. https://doi.org/10.1007/s00204-016-1772-1 PubMed DOI

Yamada H, Urata C, Aoyama Y et al (2012) Preparation of colloidal mesoporous silica nanoparticles with different diameters and their unique degradation behavior in static aqueous systems. Chem Mater 24:1462–1471. https://doi.org/10.1021/cm3001688 DOI

Yanagisawa T, Shimizu T, Kuroda K, Kato C (1990) Trimethylsilyl derivatives of alkyltrimethylammonium-kanemite complexes and their conversion to microporous SiO2 materials. BCSJ 63:1535–1537. https://doi.org/10.1246/bcsj.63.1535 DOI

Yang J, Fan L, Wang F et al (2016) Rapid-releasing of HI-6 via brain-targeted mesoporous silica nanoparticles for nerve agent detoxification. Nanoscale 8:9537–9547. https://doi.org/10.1039/C5NR06658A PubMed DOI

Yang S, Li X, Zeng G et al (2021) Materials Institute Lavoisier (MIL) based materials for photocatalytic applications. Coord Chem Rev 438:213874. https://doi.org/10.1016/j.ccr.2021.213874 DOI

Zdarova Karasova J, Kassa J, Hepnarova V et al (2022) Toxicity, pharmacokinetics, and effectiveness of the ortho-chlorinated bispyridinium oxime, K870. Food Chem Toxicol 167:113236. https://doi.org/10.1016/j.fct.2022.113236 PubMed DOI

Zhang Y, Wang J, Bai X et al (2012) Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol Pharm 9:505–513. https://doi.org/10.1021/mp200287c PubMed DOI

Zhang RH, Li LQ, Wang C et al (2015) Pretreatment with huperzine A-loaded poly(lactide-co-glycolide) nanoparticles protects against lethal effects of soman-induced in mice. Key Eng Mater 645–646:1374–1382. https://doi.org/10.4028/www.scientific.net/KEM.645-646.1374 DOI

Zhang X, Xu X, Li S et al (2018) A systematic evaluation of the biocompatibility of cucurbit[7]uril in mice. Sci Rep 8:8819. https://doi.org/10.1038/s41598-018-27206-6 PubMed DOI PMC

Zhang Y, He J, Shen L et al (2021) Brain-targeted delivery of obidoxime, using aptamer-modified liposomes, for detoxification of organophosphorus compounds. J Control Release 329:1117–1128. https://doi.org/10.1016/j.jconrel.2020.10.039 PubMed DOI

Zhao Y, Trewyn BG, Slowing II, Lin VS-Y (2009) Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J Am Chem Soc 131:8398–8400. https://doi.org/10.1021/ja901831u PubMed DOI

Zhao D, Liu J, Zhang L et al (2022) Loading and sustained release of pralidoxime chloride from swellable MIL-88B(Fe) and its therapeutic performance on mice poisoned by neurotoxic agents. Inorg Chem 61:1512–1520. https://doi.org/10.1021/acs.inorgchem.1c03227 PubMed DOI

Zhao D, Liu J, Zhou Y et al (2023) Penetrating the blood–brain barrier for targeted treatment of neurotoxicant poisoning by nanosustained-released 2-PAM@VB1-MIL-101-NH2(Fe). ACS Appl Mater Interfaces. https://doi.org/10.1021/acsami.2c18929 PubMed DOI PMC

Zheng M, Pan M, Zhang W et al (2021) Poly(α-l-lysine)-based nanomaterials for versatile biomedical applications: current advances and perspectives. Bioact Mater 6:1878–1909. https://doi.org/10.1016/j.bioactmat.2020.12.001 PubMed DOI

Zhi K, Raji B, Nookala AR et al (2021) PLGA nanoparticle-based formulations to cross the blood–brain barrier for drug delivery: from R&D to cGMP. Pharmaceutics 13:500. https://doi.org/10.3390/pharmaceutics13040500 PubMed DOI PMC

Zhou “Joe” H-C, Kitagawa S (2014) Metal-organic frameworks (MOFs). Chem Soc Rev 43:5415–5418. https://doi.org/10.1039/C4CS90059F DOI

Zhu H, Ka B, Murad F (2007) Nitric oxide accelerates the recovery from burn wounds. World J Surg 31:624–631. https://doi.org/10.1007/s00268-007-0727-3 PubMed DOI

Zhuang Q, Franjesevic AJ, Corrigan TS et al (2018) Demonstration of in vitro resurrection of aged acetylcholinesterase after exposure to organophosphorus chemical nerve agents. J Med Chem 61:7034–7042. https://doi.org/10.1021/acs.jmedchem.7b01620 PubMed DOI

Zorbaz T, Malinak D, Maraković N et al (2018) Pyridinium oximes with ortho-positioned chlorine moiety exhibit improved physicochemical properties and efficient reactivation of human acetylcholinesterase inhibited by several nerve agents. J Med Chem 61:10753–10766. https://doi.org/10.1021/acs.jmedchem.8b01398 PubMed DOI

Zorbaz T, Mišetić P, Probst N et al (2020) Pharmacokinetic evaluation of brain penetrating morpholine-3-hydroxy-2-pyridine oxime as an antidote for nerve agent poisoning. ACS Chem Neurosci 11:1072–1084. https://doi.org/10.1021/acschemneuro.0c00032 PubMed DOI

Zorbaz T, Malinak D, Hofmanova T et al (2022) Halogen substituents enhance oxime nucleophilicity for reactivation of cholinesterases inhibited by nerve agents. Eur J Med Chem 238:114377. https://doi.org/10.1016/j.ejmech.2022.114377 PubMed DOI

Synthesis and Evaluation of Halogenated Pralidoximes in Reactivation of Organophosphate-Inhibited Cholinesterases